Genetic Engineering & Biotechnology News (GEN)
Preclinical models of cancer need to raise up their game. They already perform at a high level, increasing the efficiency of drug development, individualizing patient treatment, and uncovering anticancer immune mechanisms. Going forward, however, preclinical models will also have to contend with the challenge posed by cancer immunotherapy. Essentially, cancer immunotherapy calls on mouse makers, both commercial and academic, to capture the complexities of the human immune system.
Preclinical model development has progressed from mice that lack an immune system and support the growth of implanted tumors from human cancers—that is, patient-derived xenograft (PDX) mice—to mice that incorporate humanized immune systems.